Organon & Co. (NYSE:OGN) said on Sunday it signed a definitive agreement to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion.
According to the terms of the agreement, Organon shareholders will receive $14 per share in cash, representing a 103% premium to Organon’s closing share price on April 9. The deal is expected to close in early 2027 if required approvals are secured.
The $11.75 Billion Acquisition
Organon, which was spun off from Merck & Co Inc. (NYSE:MRK) in 2021, sells more than 70 products across Women’s Health and General Medicines, including biosimilars, and markets them in more than 140 countries.
The transaction was approved by the Boards of Directors of both Organon and Sun Pharma. Organon’s portfolio, global reach, and strong stakeholder relationships are expected to complement Sun Pharma’s existing strengths and further drive long-term value creation.
The proposed acquisition of Organon aligns with Sun Pharma’s strategy to enhance its global footprint, following a period of extensive due diligence that lasted over three months. …
This post was originally published here
